Potential Weak Interaction
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied. Emtricitabine and tenofovir are eliminated renally. Letermovir is partly eliminated by glucuronidation via UGT1A1/3, but is largely eliminated unchanged in the bile. Letermovir inhibits OAT3 but this does not impact emtricitabine elimination. Tenofovir is mainly eliminated by OAT1 and to a lesser extent by OAT3. Inhibition of OAT3 by letermovir could potentially increase tenofovir exposure, although to a limited extent. Letermovir moderately induces intestinal P-gp, however, this is unlikely to alter tenofovir-DF absorption.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking